These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21293013)

  • 1. Tissue plasminogen activator for stroke and concomitant influenza infection: is this a dangerous combination?
    Grau AJ
    Stroke; 2011 Mar; 42(3):585-6. PubMed ID: 21293013
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of tissue plasminogen activator, ischemic stroke, and potential legal issues.
    Liang BA; Lew R; Zivin JA
    Arch Neurol; 2008 Nov; 65(11):1429-33. PubMed ID: 19001160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue plasminogen activator-induced reperfusion injury after stroke revisited.
    Hermann DM; Matter CM
    Circulation; 2007 Jul; 116(4):363-5. PubMed ID: 17646593
    [No Abstract]   [Full Text] [Related]  

  • 4. Is tissue plasminogen activator a threat to neurons?
    Traynelis SF; Lipton SA
    Nat Med; 2001 Jan; 7(1):17-8. PubMed ID: 11135603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombolysis in very old people with stroke: stroke subtypes, patterns, complications, and clinical outcome.
    Förster A; Szabo K; Kreisel S; Shah YP; Kern R; Griebe M; Hennerici MG
    J Am Geriatr Soc; 2011 Jan; 59(1):178-80. PubMed ID: 21226699
    [No Abstract]   [Full Text] [Related]  

  • 6. [Can the symptoms of stroke be limited?].
    Lindsberg PJ; Kaste M
    Duodecim; 1997; 113(18):1765-70. PubMed ID: 10892068
    [No Abstract]   [Full Text] [Related]  

  • 7. Stroke: success for extending acute treatment.
    Lees KR
    Lancet Neurol; 2009 Jan; 8(1):2-4. PubMed ID: 19081499
    [No Abstract]   [Full Text] [Related]  

  • 8. The weight of tissue plasminogen activator dose in overweight patients with strokes.
    Rubiera M; Molina CA
    Stroke; 2011 Jun; 42(6):1503-4. PubMed ID: 21493912
    [No Abstract]   [Full Text] [Related]  

  • 9. Orolingual angioedema associated with olmesartan use after recombinant tissue plasminogen activator treatment of acute stroke.
    Wang S; Bi X; Shan L; Zhou Y
    Ann Allergy Asthma Immunol; 2014 Feb; 112(2):177-8. PubMed ID: 24468260
    [No Abstract]   [Full Text] [Related]  

  • 10. Stroke.
    Choi D
    Neurobiol Dis; 2000 Oct; 7(5):552-8. PubMed ID: 11042076
    [No Abstract]   [Full Text] [Related]  

  • 11. Physician knowledge of the benefits, risks, and contraindications of tissue plasminogen activator for acute ischemic stroke.
    Merino JG; Silver B; Wong E; Demaerschalk B; Tamayo A; Hachinski V
    Stroke; 2001 Sep; 32(9):2208-9. PubMed ID: 11546923
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination stroke therapy: easy as APC?
    Lo EH
    Nat Med; 2004 Dec; 10(12):1295-6. PubMed ID: 15580249
    [No Abstract]   [Full Text] [Related]  

  • 13. Agreement with evidence for tissue Plasminogen Activator use among emergency physicians: a cross-sectional survey.
    Grady AM; Bryant J; Carey ML; Paul CL; Sanson-Fisher RW; Levi CR
    BMC Res Notes; 2015 Jun; 8():267. PubMed ID: 26111807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolysis for concomitant acute stroke and pulmonary embolism.
    Allport LE; Butcher KS
    J Clin Neurosci; 2008 Aug; 15(8):917-20. PubMed ID: 18474426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post stroke intervention: is the window widening?
    Zhan X; Kuczynski B; Sharp FR
    Neuropharmacology; 2011 May; 60(6):1000-2. PubMed ID: 21315742
    [No Abstract]   [Full Text] [Related]  

  • 16. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke.
    Lapergue B; Dang BQ; Desilles JP; Ortiz-Munoz G; Delbosc S; Loyau S; Louedec L; Couraud PO; Mazighi M; Michel JB; Meilhac O; Amarenco P
    Stroke; 2013 Mar; 44(3):699-707. PubMed ID: 23422087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The intervention treatment of neuroprotection for ischemic stroke].
    Wang YL; Liang H; Song SL
    Sheng Li Ke Xue Jin Zhan; 2012 Aug; 43(4):279-82. PubMed ID: 23189623
    [No Abstract]   [Full Text] [Related]  

  • 18. 4.5 hours: the new time window for tissue plasminogen activator in stroke.
    Davis SM; Donnan GA
    Stroke; 2009 Jun; 40(6):2266-7. PubMed ID: 19407232
    [No Abstract]   [Full Text] [Related]  

  • 19. Widespread subcutaneous haematoma after thrombolytic therapy in stroke patients. Mild falls at stroke onset may be dangerous.
    Mirowska-Guzel D; Kobayashi A; Członkowska A
    Neurol Neurochir Pol; 2006; 40(6):536-8. PubMed ID: 17199181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of Early Arterial Recanalization and Tissue Fate in the Selection of Patients With the Greatest Potential to Benefit From Intravenous Tissue-Type Plasminogen Activator.
    Leiva-Salinas C; Patrie JT; Xin W; Michel P; Jovin T; Wintermark M
    Stroke; 2016 Feb; 47(2):397-403. PubMed ID: 26696647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.